Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, With Chronic Hepatitis C Infection
Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, With Chronic Hepatitis C Infection
复制标题
DOI：
10.1097/mpg.0000000000001838
复制
发表时间：
2018-03-01
影响因子：
2.9
通讯作者：
Yakoot, Mostafa
中科院分区：
文献类型：
--
作者：
El-Shabrawi, Mortada H.;Abdo, Alaa M.;Yakoot, Mostafa
最近，索索布韦和固定剂量的索索布韦/来地帕斯韦组合被批准用于治疗青少年慢性丙型肝炎病毒感染，标准是12岁及以上或体重至少35公斤。在这里，我们介绍了连续10名慢性丙型肝炎青少年患者的试点单一队列的结果，对那些获得非常快速病毒学应答(VRVR)的患者和对没有达到非常快速病毒学应答(VRVR)的患者分别进行为期8周和12周的双效索非司布韦/达拉塔韦治疗。所有患者在第2周达到vRVR，并完成缩短的8周疗程。所有患者(10/10)(100%[可信区间72.25~100%])在治疗后12周获得持续的vRVR，耐受性良好，未发生严重不良事件。这些数据可以为我们建议的针对青少年使用索非司布韦/达拉塔韦的双重治疗方案提供支持，特别是对于那些获得vRVR的人来说，这一方案可以缩短疗程。建议进行更大规模的随机对照研究。
Recently, sofosbuvir and the fixed-dose combination of sofosbuvir/ledipasvir were approved for the treatment of chronic hepatitis C virus infection in adolescents, criteria being 12 years old and above or weighing at least 35 kg. Here we present the results of a pilot single cohort of 10 consecutive adolescent patients with chronic hepatitis C virus and treated with dual sofosbuvir/daclatasvir therapy for a response-tailored duration of 8 weeks for those who achieved very rapid virologic response (vRVR) and 12 weeks for those who did not. All patients achieved vRVR at week 2 and completed the shortened 8 weeks course. All patients (10/10) (100% [confidence interval 72.25-100%]) achieved sustained vRVR at week 12 post-treatment with good tolerability and no serious adverse events. These data could provide support to our suggested response-tailored protocol of dual therapy with sofosbuvir/daclatasvir in adolescents particularly for shortened duration in those who achieved vRVR. Further larger randomized controlled studies are recommended.